Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

Ascher-Svanum, Haya; Baojin Zhu; Faries, Douglas; Landbloom, Ron; Swartz, Marvin; Swanson, Jeff
January 2006
BMC Psychiatry;2006, Vol. 6, p8
Academic Journal
Background: There is an ongoing debate over whether atypical antipsychotics are more effective than typical antipsychotics in the treatment of schizophrenia. This naturalistic study compares atypical and typical antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in the treatment of schizophrenia. Methods: We used data from a large, 3-year, observational, non-randomized, multisite study of schizophrenia, conducted in the U.S. between 7/1997 and 9/2003. Patients who were initiated on oral atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine, or ziprasidone) or oral typical antipsychotics (low, medium, or high potency) were compared on time to all-cause medication discontinuation for 1 year following initiation. Treatment group comparisons were based on treatment episodes using 3 statistical approaches (Kaplan-Meier survival analysis, Cox Proportional Hazards regression model, and propensity score-adjusted bootstrap resampling methods). To further assess the robustness of the findings, sensitivity analyses were performed, including the use of (a) only 1 medication episode for each patient, the one with which the patient was treated first, and (b) all medication episodes, including those simultaneously initiated on more than 1 antipsychotic. Results: Mean time to all-cause medication discontinuation was longer on atypical (N = 1132, 256.3 days) compared to typical antipsychotics (N = 534, 197.2 days; p < .01), and longer on atypicals compared to typicals of high potency (N = 320, 187.5 days; p < .01), medium potency (N = 140, 213.5 days; p < .01), and low potency (N = 74, 208.7 days; p < .01). Among the atypicals, only clozapine, olanzapine, and risperidone had significantly longer time to all-cause medication discontinuation compared to typicals, regardless of potency level, and compared to haloperidol with prophylactic anticholinergic treatment. When compared to perphenazine, a medium-potency typical antipsychotic, only clozapine and olanzapine had a consistently and significantly longer time to all-cause medication discontinuation. Results were confirmed by sensitivity analyses. Conclusion: In the usual care of schizophrenia patients, time to medication discontinuation for any cause appears significantly longer for atypical than typical antipsychotics regardless of the typical antipsychotic potency level. Findings were primarily driven by clozapine and olanzapine, and to a lesser extent by risperidone. Furthermore, only clozapine and olanzapine therapy showed consistently and significantly longer treatment duration compared to perphenazine, a medium-potency typical antipsychotic.


Related Articles

  • Effects of long-term treatment with antipsychotics on serum leptin levels. Herrán, Andrés; García-Unzueta, María Teresa; Amado, José Antonio; de la Maza, María Teresa; Álvarez, Concepción; Vázquez-Barquero, José Luis; Herrán, A; García-Unzueta, M T; Amado, J A; de La Maza, M T; Alvarez, C; Vázquez-Barquero, J L // British Journal of Psychiatry;Jul2001, Vol. 179, p59 

    Background: Abnormal regulation of the adipocyte-derived hormone leptin could play a role in body weight gain induced by antipsychotics.Aims: To study the effects of long-term antipsychotic treatment on leptin levels in patients with schizophrenia.Method:...

  • Olanzapine and tardive dyskinesia. Woods, S. W. // British Journal of Psychiatry;Oct99, Vol. 175, p391 

    A letter to the editor is presented in response to the article "Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol," by C.M. Beasley and colleagues in volume 174.

  • Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. Johnsen, Erik; A.^Kroken, Rune; Wentzel-Larsen, Tore; A.^Jørgensen, Hugo // BMC Psychiatry;2010, Vol. 10, p26 

    Background: No clear recommendations exist regarding which antipsychotic drug should be prescribed first for a patient suffering from psychosis. The primary aims of this naturalistic study were to assess the head-to-head effectiveness of first-line second-generation antipsychotics with regards...

  • Paliperidone: the evidence of its therapeutic value in schizophrenia. Kantrowitz, Joshua; Citrome, Leslie // Core Evidence;2008, Vol. 2 Issue 4, p261 

    Introduction: Paliperidone, the 9-hydroxy metabolite of risperidone, is a second-generation antipsychotic that was recently approved for the treatment of schizophrenia. It is marketed as an improvement over risperidone, but is likely to be considerably more costly when risperidone is no longer...

  • Correlation of qEEG with PET in Schizophrenia. Alper, Kenneth; Günther, Wilfred; Prichep, Leslie S.; John, E. Roy; Brodie, Jonathan // Neuropsychobiology;1998, Vol. 38 Issue 1, p50 

    PET relative metabolism was correlated with quantitative EEG in 9 schizophrenic patients. The PET metabolic regions of interest were the frontal lobes, thalamus and basal ganglia, and right and left temporal lobes. Significant positive correlations were seen for the frontal lobes and delta EEG...

  • List of Drugs in Development for Neurodegenerative Diseases. Pogačić, Vanda; Herling, Paul // Neurodegenerative Diseases;2007, Vol. 4 Issue 6, p443 

    Background/Aims: Alzheimer’s disease (AD) is characterized by extracellular Aβ peptide deposition originating from amyloid precursor protein cleavage and intracellular neurofibrillary tangles resulting from pathological tau protein aggregation. These processes are accompanied by...

  • Involvement of Basal Ganglia Network in Motor Disabilities Induced by Typical Antipsychotics. Chetrit, Jonathan; Ballion, Bérangère; Laquitaine, Steeve; Belujon, Pauline; Morin, Stéphanie; Taupignon, Anne; Bioulac, Bernard; Gross, Christian E.; Benazzouz, Abdelhamid // PLoS ONE;2009, Vol. 4 Issue 7, p1 

    Background: Clinical treatments with typical antipsychotic drugs (APDs) are accompanied by extrapyramidal motor sideeffects (EPS) such as hypokinesia and catalepsy. As little is known about electrophysiological substrates of such motor disturbances, we investigated the effects of a typical APD,...

  • Choking deaths: the role of antipsychotic medication. Ruschena, D.; Mullen, P. E.; Palmer, S.; Burgess, P.; Cordner, S. M.; Drummer, O. H.; Wallace, C.; Barry-Walsh, J. // British Journal of Psychiatry;Nov2003, Vol. 183, p446 

    Background: An increased risk of choking associated with antipsychotic medication has been repeatedly postulated.Aims: To examine this association in a large number of cases of choking deaths.Method: Cases of individuals who had died because of choking were...

  • Quantitative EEG in Schizophrenic Patients before and during Pharmacotherapy. Begić, Dražen; Hotujac, Ljubomir; Jokić-Begić, Nataša // Neuropsychobiology;2000, Vol. 41 Issue 3, p166 

    The aim of the study was to determine the possible differences in quantitative EEG parameters of schizophrenic patients before and during therapy with neuroleptics. First EEG recordings were obtained from schizophrenic patients (n = 50) who had not been taking any medicaments during the...

  • Attitudes to antipsychotic drugs and their side effects: a comparison between general practitioners and the general population. Helbling, Josef; Ajdacic-Gross, Vladeta; Lauber, Christoph; Weyermann, Ruth; Burns, Tom; Rössler, Wulf // BMC Psychiatry;2006, Vol. 6, p42 

    Background: Attitudes towards antipsychotic medication play an important part in the treatment for schizophrenia and related disorders. We aimed measuring general practitioners' attitudes to antipsychotic drugs and their adverse side effects and comparing these with the attitudes of the general...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics